Physician profile
Mark S Newth
NPI 1689644569
$1,130.36
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $976 · 2020: $115 · 2021: $26.55 · 2022: $12.81.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $222.38 | 2019-2022 | |
| Abbvie INC. | $206.39 | 2019-2020 | |
| Lilly USA, LLC | $162.83 | 2019-2020 | |
| Novo Nordisk INC | $149.21 | 2019-2020 | |
| Glaxosmithkline, LLC. | $90.37 | 2019 | |
| Genentech USA, INC. | $55.86 | 2019 | |
| Pfizer INC. | $36.92 | 2019 | |
| Allergan, INC. | $34.87 | 2019 | |
| Tersera Therapeutics LLC | $34.02 | 2019 | |
| Alexion Pharmaceuticals, INC. | $30.12 | 2019 | |
| Celgene Corporation | $27.41 | 2019 | |
| Astellas Pharma US INC | $26.79 | 2019-2020 | |
| Shire North American Group INC | $14.62 | 2019 | |
| Strongbridge US INC. | $14.08 | 2019 | |
| Janssen Biotech, INC. | $12.69 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $11.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Newth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.